Cost-comparison of Prostate Cancer Screening Versus Not Screening PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Cost-comparison of Prostate Cancer Screening Versus Not Screening PDF full book. Access full book title Cost-comparison of Prostate Cancer Screening Versus Not Screening by Bill Fell. Download full books in PDF and EPUB format.
Author: Bill Fell Publisher: ISBN: Category : Medical screening Languages : en Pages : 122
Book Description
Prostate cancer is a common form of cancer in men. In fact, prostate cancer has the highest incidence of any cancer in men. Prostate cancer is not only common, it carries a significant financial burden. The cost of prostate cancer is 11.3% of all cancer expenditures. If after a DRE the prostate is enlarged, or if the PSA is elevated, then a biopsy of the prostate would be recommended. Under the best of circumstances, cancer diagnoses will be missed and many will undergo unnecessary biopsy, etc. The focus of this paper was the cost-utility of screening with the PSA test. The cost differences between screening and not screening was compared. A Markov analysis and a Monte Carlo simulation were utilized to provide a basis for conclusion. The primary finding is that the costs associated with screening are much higher than those of not screening. Additional findings are that the specificity of the PSA test, the first year treatment costs, and the utility/outcomes of screening have an impact on the cost-utility of screening. The conclusion, however, is that the improvements in these factors would have to be significant to impact the case for screening. Until longitudinal studies are completed, it is not cost-effective to screen for prostate cancer.
Author: Bill Fell Publisher: ISBN: Category : Medical screening Languages : en Pages : 122
Book Description
Prostate cancer is a common form of cancer in men. In fact, prostate cancer has the highest incidence of any cancer in men. Prostate cancer is not only common, it carries a significant financial burden. The cost of prostate cancer is 11.3% of all cancer expenditures. If after a DRE the prostate is enlarged, or if the PSA is elevated, then a biopsy of the prostate would be recommended. Under the best of circumstances, cancer diagnoses will be missed and many will undergo unnecessary biopsy, etc. The focus of this paper was the cost-utility of screening with the PSA test. The cost differences between screening and not screening was compared. A Markov analysis and a Monte Carlo simulation were utilized to provide a basis for conclusion. The primary finding is that the costs associated with screening are much higher than those of not screening. Additional findings are that the specificity of the PSA test, the first year treatment costs, and the utility/outcomes of screening have an impact on the cost-utility of screening. The conclusion, however, is that the improvements in these factors would have to be significant to impact the case for screening. Until longitudinal studies are completed, it is not cost-effective to screen for prostate cancer.
Author: Publisher: ISBN: Category : Languages : en Pages : 130
Book Description
In recent years, the prostate cancer diagnosis rate has increased dramatically, with a slower increase in age-specific mortality. At least in part, the increasing incidence undoubtedly reflects more aggressive efforts at early detection of prostate cancer, particularly through the use of a new blood test, prostate-specific antigen (PSA). This background paper examines the implications of a potential Medicare benefit to cover prostate cancer screening using a combination of the PSA and digital rectal examination (DRE), a time-honored test performed in the physician's office. OTA concludes that the evidence of benefit for prostate cancer screening is substantially weaker than for preventive services already covered by Medicare. Because the scientific knowledge is limited, but the consequences of prostate cancer and its treatment are serious, an informed patient and his physician could equally well decide to receive screening or forgo it. Medicare reimbursement could be one means of insuring that out-of-pocket expenses not impede well-informed decision-making between physician and patient about whether to receive screening.
Author: United States. Congress. Office of Technology Assessment Publisher: U.S. Government Printing Office ISBN: Category : Health & Fitness Languages : en Pages : 162
Author: National Research Council Publisher: National Academies Press ISBN: 0309170133 Category : Medical Languages : en Pages : 564
Book Description
Cancer ranks second only to heart disease as a leading cause of death in the United States, making it a tremendous burden in years of life lost, patient suffering, and economic costs. Fulfilling the Potential for Cancer Prevention and Early Detection reviews the proof that we can dramatically reduce cancer rates. The National Cancer Policy Board, part of the Institute of Medicine, outlines a national strategy to realize the promise of cancer prevention and early detection, including specific and wide-ranging recommendations. Offering a wealth of information and directly addressing major controversies, the book includes: A detailed look at how significantly cancer could be reduced through lifestyle changes, evaluating approaches used to alter eating, smoking, and exercise habits. An analysis of the intuitive notion that screening for cancer leads to improved health outcomes, including a discussion of screening methods, potential risks, and current recommendations. An examination of cancer prevention and control opportunities in primary health care delivery settings, including a review of interventions aimed at improving provider performance. Reviews of professional education and training programs, research trends and opportunities, and federal programs that support cancer prevention and early detection. This in-depth volume will be of interest to policy analysts, cancer and public health specialists, health care administrators and providers, researchers, insurers, medical journalists, and patient advocates.
Author: Imogen Evans Publisher: Pinter & Martin Publishers ISBN: 1905177488 Category : Health & Fitness Languages : en Pages : 187
Book Description
This work provides a thought-provoking account of how medical treatments can be tested with unbiased or 'fair' trials and explains how patients can work with doctors to achieve this vital goal. It spans the gamut of therapy from mastectomy to thalidomide and explores a vast range of case studies.
Author: Andrew W. Bruce Publisher: Springer Science & Business Media ISBN: 1447113985 Category : Medical Languages : en Pages : 363
Book Description
Carcinoma of the prostate increasingly dominates the attention of urologists for both scientific and clinical reasons. The search for an explanation and the prediction of the variable behaviour of the malignant prostatic cell continues unabated. The search for more precise tumour staging and more effective treatment is equally vigorous. Editors Andrew Bruce and John Trachtenberg have assembled acknowledged leaders in prostate cancer to present those areas of direct interest to the clinician. There are a number of other topics that might have been considered but most of these, such as experimental tumour models or biochemical factors affecting cell growth, still lack immediate application for the clinician. Carcinoma of the prostate continues to have its highest incidence in the western world, and the difference in comparison with the incidence in the Far East appears to be real and not masked by diagnostic or other factors. A number of other epidemiological aspects need careful analysis: Is the incidence increasing? Is the survival improving? Is the prognosis worse in the younger patient? Epidemiological data are easily misused and misinterpreted so that a precise analysis of the known facts makes an important opening chapter to this book.
Author: Robert S. Kaplan Publisher: Harvard Business Press ISBN: 1422163563 Category : Business & Economics Languages : en Pages : 283
Book Description
In the classroom, ABC looks like a great way to manage a company’s resources. But many executives who have tried to implement ABC on a large scale in their organizations have found the approach limiting and frustrating. Why? The employee surveys that companies used to estimate resources required for business activities proved too time-consuming, expensive, and irritating to employees. This book shows you how to implement time-driven activity-based costing (TDABC), an easier and more powerful way to implement ABC. You can now estimate directly the resource demands imposed by each business transaction, product, or customer. The payoff? You spend less time and money obtaining and maintaining TDABC data—and more time addressing problems that TDABC reveals, such as inefficient processes, unprofitable products and customers, and excess capacity. The authors also show how to use TDABC to link strategic planning to operational budgeting, to enhance the due diligence process for mergers and acquisitions, and to support continuous improvement activities such as lean management and benchmarking. In presenting their model, the authors define the two questions required to build TDABC: 1) How much does it cost per time unit to supply resource capacity for each business process? 2) How much resource capacity (time) is required to perform work for a company’s many transactions, products, and customers? The book demonstrates how to develop simple, valid answers to these two questions. Kaplan and Anderson illustrate the TDABC approach with a wealth of case studies, in diverse settings, based on actual implementations.
Author: Bill Fell
Author: Bill Fell
Author: DIANE Publishing Company
Author: 
Author: 
Author: United States. Congress. Office of Technology Assessment
Author: National Research Council
Author: Imogen Evans
Author: Andrew W. Bruce
Author: Myron P. Tannenbaum
Author: Robert S. Kaplan